MX336751B - Composicion farmaceutica para tratar un sindrome metabolico. - Google Patents
Composicion farmaceutica para tratar un sindrome metabolico.Info
- Publication number
- MX336751B MX336751B MX2012008092A MX2012008092A MX336751B MX 336751 B MX336751 B MX 336751B MX 2012008092 A MX2012008092 A MX 2012008092A MX 2012008092 A MX2012008092 A MX 2012008092A MX 336751 B MX336751 B MX 336751B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- metabolic syndrome
- treating
- adipositas
- dyslipidemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
La presente invención se refiere a una composición farmacéutica que contiene al menos un compuesto FGF-21 (factor de crecimiento de fibroblastos 21), al menos un agonista del GLP-1R (receptor del péptido 1 similar al glucagón) y opcionalmente al menos un fármaco antidiabético y/o al menos un inhibidor de DPP-4 (dipeptidil peptidasa-4) para el tratamiento de al menos un síndrome metabólico y/o la aterosclerosis, en particular diabetes, dislipidemia, obesidad y/u obesidad patológica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305070A EP2359843A1 (en) | 2010-01-21 | 2010-01-21 | Pharmaceutical composition for treating a metabolic syndrome |
PCT/EP2011/050793 WO2011089203A1 (en) | 2010-01-21 | 2011-01-21 | Pharmaceutical composition for treating a metabolic syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012008092A MX2012008092A (es) | 2012-07-30 |
MX336751B true MX336751B (es) | 2016-01-29 |
Family
ID=41718306
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008092A MX336751B (es) | 2010-01-21 | 2011-01-21 | Composicion farmaceutica para tratar un sindrome metabolico. |
MX2015007689A MX361922B (es) | 2010-01-21 | 2011-01-21 | Composición farmacéutica para tratar un síndrome metabólico. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015007689A MX361922B (es) | 2010-01-21 | 2011-01-21 | Composición farmacéutica para tratar un síndrome metabólico. |
Country Status (33)
Country | Link |
---|---|
US (4) | US20130203651A1 (es) |
EP (7) | EP2460527A1 (es) |
JP (3) | JP5925130B2 (es) |
KR (2) | KR20120123445A (es) |
CN (1) | CN102753192B (es) |
AR (1) | AR079939A1 (es) |
AU (2) | AU2011208650B2 (es) |
BR (1) | BR112012017949A2 (es) |
CA (1) | CA2787131A1 (es) |
CL (1) | CL2012002031A1 (es) |
CO (1) | CO6592082A2 (es) |
CY (2) | CY1116026T1 (es) |
DK (2) | DK3216459T3 (es) |
ES (3) | ES2703581T3 (es) |
HK (2) | HK1173073A1 (es) |
HR (2) | HRP20150029T1 (es) |
HU (1) | HUE041442T2 (es) |
IL (2) | IL220862A0 (es) |
LT (1) | LT3216459T (es) |
MA (1) | MA33931B1 (es) |
MX (2) | MX336751B (es) |
NZ (1) | NZ601306A (es) |
PL (2) | PL2525807T3 (es) |
PT (2) | PT2525807E (es) |
RS (1) | RS53742B1 (es) |
RU (2) | RU2732703C2 (es) |
SG (2) | SG10201500465XA (es) |
SI (2) | SI3216459T1 (es) |
TR (1) | TR201820147T4 (es) |
TW (2) | TWI623320B (es) |
UY (1) | UY33194A (es) |
WO (1) | WO2011089203A1 (es) |
ZA (1) | ZA201204996B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2349324T (pt) | 2008-10-17 | 2017-12-06 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
EP2498801B1 (de) | 2009-11-13 | 2018-01-24 | Sanofi-Aventis Deutschland GmbH | HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN |
PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
EP2611458B1 (en) | 2010-08-30 | 2016-09-21 | Sanofi-Aventis Deutschland GmbH | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
SG10201806648TA (en) | 2011-07-01 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for treatment of metabolic disorders and diseases |
EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
KR20150043505A (ko) * | 2012-09-07 | 2015-04-22 | 사노피 | 대사 증후군의 치료용 융합 단백질 |
NZ630484A (en) | 2012-11-28 | 2017-04-28 | Ngm Biopharmaceuticals Inc | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN105008548B (zh) | 2012-12-27 | 2020-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法 |
ES2753264T3 (es) | 2013-10-28 | 2020-04-07 | Ngm Biopharmaceuticals Inc | Modelos de cáncer y métodos asociados |
SI3097122T1 (sl) | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo |
US10532083B2 (en) | 2014-02-13 | 2020-01-14 | Technische Universität München | Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8 |
JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
JP6672175B2 (ja) * | 2014-05-07 | 2020-03-25 | ノヴォ ノルディスク アー/エス | Glp−1及び抗il−21を使用した1型糖尿病の治療 |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN104383523A (zh) * | 2014-10-22 | 2015-03-04 | 山西医科大学 | Cjc-1131降糖药物在治疗阿尔茨海默病的用途 |
UA123763C2 (uk) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
WO2018115401A1 (en) * | 2016-12-22 | 2018-06-28 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
JP2018110304A (ja) | 2016-12-28 | 2018-07-12 | パナソニックIpマネジメント株式会社 | 監視システム、監視方法、及びプログラム |
US20220127322A1 (en) * | 2017-03-14 | 2022-04-28 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
WO2019149782A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
JP7475276B2 (ja) | 2018-02-08 | 2024-04-26 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Fgf21バリアント、融合タンパク質及びそれらの適用 |
JP2021528422A (ja) * | 2018-06-21 | 2021-10-21 | サノフイSanofi | 最適化された活性比を有するfgf21化合物/glp−1rアゴニストの組合せ |
CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
KR20210149366A (ko) * | 2020-06-02 | 2021-12-09 | 주식회사 고바이오랩 | Icam-2에 결합하는 물질을 유효성분으로 포함하는 대사질환 예방 또는 치료용 약학 조성물 |
US20220010021A1 (en) | 2020-07-02 | 2022-01-13 | Sanofi | FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides |
WO2022144021A1 (zh) * | 2021-01-04 | 2022-07-07 | 华领医药技术(上海)有限公司 | Dorzagliatin和胰高血糖素样肽-1类似物的药物组合物 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK347086D0 (da) | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
JP2606915B2 (ja) | 1987-02-25 | 1997-05-07 | ノボ ノルディスク アクティーゼルスカブ | 新規インシュリン誘導体 |
US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
EP1132404A3 (en) | 1993-09-17 | 2002-03-27 | Novo Nordisk A/S | Acylated insulin |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
JP2002112772A (ja) * | 2000-07-10 | 2002-04-16 | Takeda Chem Ind Ltd | 新規ポリペプチドおよびそのdna |
US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
AU2002322394A1 (en) | 2001-07-30 | 2003-02-17 | Eli Lilly And Company | Method for treating diabetes and obesity |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
JP2006501820A (ja) * | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法 |
EP1641483B1 (en) | 2003-06-12 | 2008-02-13 | Eli Lilly And Company | Fusion proteins |
BRPI0416683A (pt) | 2003-12-10 | 2007-01-30 | Lilly Co Eli | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 |
WO2005072769A1 (en) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
CA2557782A1 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
DK1751184T3 (da) | 2004-05-13 | 2009-11-23 | Lilly Co Eli | FGF-21 fusionsproteiner |
BRPI0514790A (pt) | 2004-09-02 | 2008-06-24 | Lilly Co Eli | muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano |
WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子21の突然変異タンパク質 |
EP2068910A2 (en) * | 2006-08-04 | 2009-06-17 | Amylin Pharmaceuticals, Inc. | Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition |
UY30820A1 (es) * | 2006-12-21 | 2008-07-03 | Centocor Inc | Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos |
AU2008232937B2 (en) * | 2007-03-30 | 2012-09-27 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
WO2009020802A2 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
EP2242505A4 (en) | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
WO2010006214A1 (en) * | 2008-07-09 | 2010-01-14 | Ambrx, Inc. | Fgf-21 neutralizing antibodies and their uses |
WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
JP2012529463A (ja) * | 2009-06-11 | 2012-11-22 | ノヴォ ノルディスク アー/エス | 2型糖尿病を治療するための、glp−1とfgf21との組合せ |
EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
-
2010
- 2010-01-21 EP EP11174543A patent/EP2460527A1/en not_active Withdrawn
- 2010-01-21 EP EP10305070A patent/EP2359843A1/en not_active Withdrawn
-
2011
- 2011-01-19 TW TW105119851A patent/TWI623320B/zh active
- 2011-01-19 TW TW100101879A patent/TWI561241B/zh active
- 2011-01-19 AR ARP110100174A patent/AR079939A1/es unknown
- 2011-01-19 UY UY0001033194A patent/UY33194A/es not_active Application Discontinuation
- 2011-01-21 CN CN201180006759.5A patent/CN102753192B/zh not_active Expired - Fee Related
- 2011-01-21 NZ NZ601306A patent/NZ601306A/xx not_active IP Right Cessation
- 2011-01-21 MX MX2012008092A patent/MX336751B/es unknown
- 2011-01-21 EP EP11700669.2A patent/EP2525807B1/en active Active
- 2011-01-21 ES ES16205881T patent/ES2703581T3/es active Active
- 2011-01-21 LT LTEP16205881.2T patent/LT3216459T/lt unknown
- 2011-01-21 TR TR2018/20147T patent/TR201820147T4/tr unknown
- 2011-01-21 DK DK16205881.2T patent/DK3216459T3/en active
- 2011-01-21 WO PCT/EP2011/050793 patent/WO2011089203A1/en active Application Filing
- 2011-01-21 EP EP20140163127 patent/EP2754449A1/en not_active Withdrawn
- 2011-01-21 PT PT117006692T patent/PT2525807E/pt unknown
- 2011-01-21 PL PL11700669T patent/PL2525807T3/pl unknown
- 2011-01-21 EP EP16205881.2A patent/EP3216459B1/en active Active
- 2011-01-21 US US13/521,275 patent/US20130203651A1/en not_active Abandoned
- 2011-01-21 RU RU2016124562A patent/RU2732703C2/ru active
- 2011-01-21 AU AU2011208650A patent/AU2011208650B2/en not_active Ceased
- 2011-01-21 KR KR1020127021708A patent/KR20120123445A/ko active Search and Examination
- 2011-01-21 PT PT16205881T patent/PT3216459T/pt unknown
- 2011-01-21 RU RU2012135686/15A patent/RU2593960C2/ru not_active IP Right Cessation
- 2011-01-21 EP EP19195239.9A patent/EP3607964B1/en active Active
- 2011-01-21 BR BR112012017949A patent/BR112012017949A2/pt not_active Application Discontinuation
- 2011-01-21 SI SI201131638T patent/SI3216459T1/sl unknown
- 2011-01-21 SI SI201130355T patent/SI2525807T1/sl unknown
- 2011-01-21 SG SG10201500465XA patent/SG10201500465XA/en unknown
- 2011-01-21 JP JP2012549361A patent/JP5925130B2/ja not_active Expired - Fee Related
- 2011-01-21 KR KR1020187012112A patent/KR20180049194A/ko not_active Application Discontinuation
- 2011-01-21 DK DK11700669.2T patent/DK2525807T3/en active
- 2011-01-21 MA MA35075A patent/MA33931B1/fr unknown
- 2011-01-21 ES ES19195239T patent/ES2930750T3/es active Active
- 2011-01-21 RS RS20150004A patent/RS53742B1/en unknown
- 2011-01-21 MX MX2015007689A patent/MX361922B/es unknown
- 2011-01-21 HU HUE16205881A patent/HUE041442T2/hu unknown
- 2011-01-21 PL PL16205881T patent/PL3216459T3/pl unknown
- 2011-01-21 ES ES11700669.2T patent/ES2529612T3/es active Active
- 2011-01-21 SG SG2012054045A patent/SG182652A1/en unknown
- 2011-01-21 CA CA2787131A patent/CA2787131A1/en not_active Abandoned
- 2011-01-21 EP EP18162214.3A patent/EP3357503B1/en active Active
-
2012
- 2012-07-04 ZA ZA2012/04996A patent/ZA201204996B/en unknown
- 2012-07-10 IL IL220862A patent/IL220862A0/en unknown
- 2012-07-20 CL CL2012002031A patent/CL2012002031A1/es unknown
- 2012-08-15 CO CO12138126A patent/CO6592082A2/es not_active Application Discontinuation
-
2013
- 2013-01-08 HK HK13100270.6A patent/HK1173073A1/xx not_active IP Right Cessation
-
2015
- 2015-01-12 HR HRP20150029AT patent/HRP20150029T1/hr unknown
- 2015-02-12 CY CY20151100146T patent/CY1116026T1/el unknown
- 2015-02-20 US US14/628,037 patent/US20150231210A1/en not_active Abandoned
-
2016
- 2016-01-29 JP JP2016015359A patent/JP6521880B2/ja active Active
- 2016-03-02 US US15/059,001 patent/US20160279199A1/en not_active Abandoned
- 2016-10-11 AU AU2016244202A patent/AU2016244202B2/en not_active Ceased
-
2018
- 2018-01-11 US US15/868,688 patent/US20180236033A1/en not_active Abandoned
- 2018-02-09 JP JP2018021608A patent/JP2018095659A/ja active Pending
- 2018-03-09 HK HK19101914.0A patent/HK1259492A1/zh unknown
- 2018-12-19 HR HRP20182158TT patent/HRP20182158T1/hr unknown
- 2018-12-21 CY CY20181101387T patent/CY1121423T1/el unknown
-
2019
- 2019-07-10 IL IL267980A patent/IL267980B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX336751B (es) | Composicion farmaceutica para tratar un sindrome metabolico. | |
TN2015000053A1 (en) | Fusion proteins for treating a metabolic syndrome | |
MX2019007584A (es) | Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada. | |
HRP20200103T1 (hr) | Analozi glukagona | |
AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
IN2014CN00782A (es) | ||
UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
PL2021337T3 (pl) | Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1 | |
MY148079A (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
ZA200808816B (en) | Pieridinyl substituted pyrrolidinones as inhibitors of 11-Beta-hydroxysteroid dehydrogenase 1 | |
CL2007003176A1 (es) | Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis. | |
BRPI0924307B8 (pt) | análogos de oxintomodulina | |
WO2011056713A3 (en) | Glp-1 receptor agonist compounds for obstructive sleep apnea | |
NZ603445A (en) | Gip-based mixed agonists for treatment of metabolic disorders and obesity | |
UA95798C2 (ru) | Производные циклогексилпиразоллактама как ингибиторы 11-бета-гидроксистероиддегидрогеназы 1 | |
DE602007007211D1 (de) | Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1 | |
EA200870472A1 (ru) | Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1 | |
WO2010054326A3 (en) | C-terminal fragments of glucagon-like peptide-1 (glp-1) | |
IN2012DN03271A (es) | ||
MX2022014368A (es) | Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo. | |
TR201900959T4 (tr) | Bi̇leşi̇mler ve bunlarin tibbi̇ kullanimi. | |
IN2012DN00977A (es) | ||
TH130088B (th) | องค์ประกอบทางเภสัชกรรมสำหรับการรักษากลุ่มอาการเกี่ยวกับเมแทบอลิก | |
TH130088A (th) | องค์ประกอบทางเภสัชกรรมสำหรับการรักษากลุ่มอาการเกี่ยวกับเมแทบอลิก | |
UA104000C2 (ru) | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |